Publications

• C.E.R.A. Administered at Extended Dosing Intervals Corrects Anemia and Maintains Stable Hemoglobin Levels in Patients with Chronic Kidney Disease (CKD) not on Dialysis
  
  Provenzano, R., Schmidt, R., Dalton, C., Beswick, R., Nassar, G., C.E.R.A. Administered at Extended Dosing Intervals Corrects Anemia and Maintains Stable Hemoglobin Levels in Patients with Chronic Kidney Disease (CKD) not on Dialysis. ESRD Forum Meeting, Baltimore, MD, 2007.
• Arterial Anastomosis Disruption in Two Kidney Recipients of Contaminated Grafts from a Donor With Gorham's Syndrome
  
  Saidi, R.F., Fasola, C., El-Ghoroury, M., Oh, H., Arterial Anastomosis Disruption in Two Kidney Recipients of Contaminated Grafts from a Donor with Gorham’s Syndrome, Transplant Proceedings, 36(5): 1392-4, June 2004.
• Use of Aldosterone Antagonists (AA) Are Associated with Achieved Blood Pressure (BP) Control in Chronic Kidney Disease (CKD)
  
  Topf, J., Steigerwalt, S., Provenzano, R., Use of Aldosterone Antagonists (AA) Are Associated with Achieved Blood Pressure (BP) Control in Chronic Kidney Disease (CKD). American Society of Nephrology 39th Annual Meeting, San Diego, CA, 2006.
• CKD (Chronic Kidney Disease) Clinics Improve Anemia, Lipids and Arrest the Decline of GFR
  
  Topf, J., Provenzano, R., Abud, G., CKD (Chronic Kidney Disease) Clinics Improve Anemia, Lipids and Arrest the Decline of GFR, American Society of Nephrology 39th Annual Meeting, San Diego, CA, 2006.
• Hyperkalemia in a Chronic Kidney Disease Clinic: Frequency, Risk Factors and Protective Agents
  
  Topf, J., Alumit, G., Hyperkalemia in a Chronic Kidney Disease Clinic: Frequency, Risk Factors and Protective Agents, American Society of Nephrology 39th Annual Meeting, San Diego, CA, 2006.
• A Double-Blind, Placebo-Controlled, Randomized Phase III Study of the Safety of Ferumoxytol – A New Intravenous Iron Replacement Therapy
  
  Singh, A., Besarab, A. Bolton, W., Pereira, B, Provenzano, R., Rao, M., Spinowitz, B., A Double-Blind, Placebo-Controlled, Randomized Phase III Study of the Safety of Ferumoxytol – A New Intravenous Iron Replacement Therapy, American Society of Nephrology 39th Annual Meeting, San Diego, CA, 2006.
• Parenteral Iron Therapy with Ferumoxytol in Hemodialysis: A Phase III Study
  
  Besarab, A., Bolton, W., Pereira, B., Provenzano, R., Singh, A., Rao, and Spinowitz, B. Parenteral Iron Therapy with Ferumoxytol in Hemodialysis: A Phase III Study, American Society of Nephrology 39th Annual Meeting, San Diego, CA, 2006.
• Ferumoxytol as Intravenous Iron Replacement Therapy in Chronic Kidney Disease (CKD) Patients Not on Dialysis – Evaluation of Safety and Efficacy in Two Phase III Studies
  
  Spinowitz, B., Besarab, A., Bolton, W., Pereira, B., Provenzano, R., Rao, M., Singh, A. Ferumoxytol as Intravenous Iron Replacement Therapy in Chronic Kidney Disease (CKD) Patients Not on Dialysis – Evaluation of Safety and Efficacy in Two Phase III Studies, American Society of Nephrology 39th Annual Meeting, San Diego, CA, 2006.
• Blood Pressure (BP) Control by Race, Gender and Chronic Kidney Disease (CKD) Stage in a CKD Clinic
  
  Topf, J., Steigerwalt, S., Provenzano, R., Blood Pressure (BP) Control by Race, Gender and Chronic Kidney Disease (CKD) Stage in a CKD Clinic, American Society of Hypertension 21st Annual Scientific Meeting, New York, NY, 2006.
• Preference for Information and Blood Pressure Control Status Influence Blood Pressure Reductions in Women,
  
  Steigerwalt, S., Makos, G., Scisney-Matlock, M., Preference for Information and Blood Pressure Control Status Influence Blood Pressure Reductions in Women, American Society of Hypertension 21st Annual Scientific Meeting, New York, NY, 2006.
• Comparison Study Between the Nocturnal Hemodialysis and the Traditional Hemodialysis
  
  Jabri, Muhammad, Topf, Joel, Comparison Study Between the Nocturnal Hemodialysis and the Traditional Hemodialysis, American College of Physicians Regional Meeting, Traverse City, MI, 2006.
• Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) Administered Once Every 2 Weeks Effectively Corrects Anemia in Patients with Chronic Kidney Disease (CKD) on Dialysis and Not on Dialysis
  
  Provenzano, R., Dougherty, F., Subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) Administered Once Every 2 Weeks Effectively Corrects Anemia in Patients with Chronic Kidney Disease (CKD) on Dialysis and Not on Dialysis. National Kidney Foundation Clinical Meetings, Chicago, IL, 2006.
• Minimal Change Disease with Incidental Mesangial IgA Deposits Preceding Hodgkin’s Lymphoma.
  
  Jefic, D., Topf, J., Minimal Change Disease with Incidental Mesangial IgA Deposits Preceding Hodgkin’s Lymphoma.  National Kidney Foundation Clinical Meetings, Chicago, IL, 2006.
• Blood Pressure (BP) Control by Race, Gender and Chronic Kidney Disease (CKD) Stage in a CKD Clinic
  
  Topf, J., Steigerwalt, S., Blood Pressure (BP) Control by Race, Gender and Chronic Kidney Disease (CKD) Stage in a CKD Clinic. National Kidney Foundation Spring Clinical Meeting, Chicago, IL, 2006.
• Aldosterone Antagonists (AA) Are Associated with Achieved Target Blood Pressure in Chronic Kidney Disease (CKD)
  
  Topf, J., Steigerwalt, S., Aldosterone Antagonists (AA) Are Associated with Achieved Target Blood Pressure in Chronic Kidney Disease (CKD).  National Kidney Foundation Spring Clinical Meeting, Chicago, IL, 2006.
• Cyanide Toxicity from Nitroprusside in a Patient with Chronic Kidney Disease
  
  [Full text available as PDF from kidney.org - Article is on page 13]
  Venugopal, A., Topf, J., Cyanide Toxicity from Nitroprusside in a Patient with Chronic Kidney Disease.  National Kidney Foundation Spring Clinical Meeting, Chicago, IL, 2006.
• Lactic Acidosis Cannot Be Used to Explain an Osmolal Gap in Patients with Potential Ethylene Glycol Toxicity: A Case Report and Review of the Literature
  
  Topf, J., Jayakar, S., Lactic Acidosis Cannot Be Used to Explain an Osmolal Gap in Patients with Potential Ethylene Glycol Toxicity: A Case Report and Review of the Literature.  National Kidney Foundation Spring Clinical Meeting, Chicago, IL, 2006.
• C-Reactive Protein Levels Do Not Predict Acute Rejection in Kidney Transplant Recipients
  
  Butcher, D., El-Ghoroury, M., Bellovich, K., Provenzano, R., C-Reactive Protein Levels Do Not Predict Acute Rejection in Kidney Transplant Recipients, National Kidney Foundation Spring Clinical Meeting, Chicago, IL, 2006.
• The Impact of Avoiding Both Steroids and Calcineurin Inhibitors on Polyomavirus-Associated Nephropathy in Kidney Transplantation
  
  Brar, N., Butcher, D., El-Ghoroury, M., Provenzano, R., The Impact of Avoiding Both Steroids and Calcineurin Inhibitors on Polyomavirus-Associated Nephropathy in Kidney Transplantation, National Kidney Foundation Spring Clinical Meeting, Chicago, IL, 2006.
• Basiliximab Versus Thymoglobulin Induction for Steroid-Free Maintenance Immunosuppression in Live Kidney Transplant Recipients
  
  Butcher, D., Aryan, M., El-Ghoroury, M., Provenzano, R., Granger, D., Oh, H., Basiliximab Versus Thymoglobulin Induction for Steroid-Free Maintenance Immunosuppression in Live Kidney Transplant Recipients. American Society of Nephrology, Philadelphia, PA, 2005.
• Pretransplant C-Reactive Protein Levels Do Not Predict Renal Function or Graft Survival at One Year
  
  Butcher, D., Kassar, A., Bellovich, K., El-Ghoroury, M., Provenzano, R., Pretransplant C-Reactive Protein Levels Do Not Predict Renal Function or Graft Survival at One Year.  American Society of Nephrology, Philadelphia, PA, 2005.
• Anemia Outcomes from a Medical-Assistant Driven Anemia Protocol to Treat Patients and Move Toward Monthly Epoetin Dosing.
  
  Topf, J., Abud, G., Maria, V., Provenzano, R., Anemia Outcomes from a Medical-Assistant Driven Anemia Protocol to Treat Patients and Move Toward Monthly Epoetin Dosing. American Society of Nephrology, Philadelphia, PA, 2005.
• Antiphospholipid Antibodies in Chronic Kidney Disease
  
  Nagrecha, M., Topf, J. Antiphospholipid Antibodies in Chronic Kidney Disease.  American Society of Nephrology, Philadelphia, PA, 2005.
• Baxiliximab Versus Thymoglobulin Induction for Steroid-Free Maintenance Immunosuppression in Live Kidney Transplant Recipients
  
  Butcher, D., El-Ghoroury, M., Provenzano, R., Granger, D., Oh, H., Baxiliximab Versus Thymoglobulin Induction for Steroid-Free Maintenance Immunosuppression in Live Kidney Transplant Recipients, Transplant Immunosuppression 2005: Improving Recipient Outcome, University of Minnesota, 2005. (Oral Presentation)
• Prevalence and Treatment of Anemia in Patients with Hypertension and Chronic Kidney Disease
  
  McClellan, W., Provenzano, R., Prevalence and Treatment of Anemia in Patients with Hypertension and Chronic Kidney Disease.  Heart Failure Society of America, 9th Annual Scientific Meeting, Boca Raton, FL, 2005.